Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia

The ability of acute myeloid leukemic (AML) blasts to differentiate into leukemic dendritic cells (DC) thus acquiring the potential to present known and unknown leukemic antigens efficiently, holds promise as a possible new treatment for AML patients with minimal residual disease. Recent advances in culture methods have made the clinical use of leukemic DC feasible. However, additional measures appear to be essential in order to potentiate vaccines and to overcome the intrinsic tolerant state of the patients immune system. This review describes ways to improve AML-DC vaccines and discusses critical aspects concerning the development of clinical vaccination protocols.

[1]  C. Coltman,et al.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.

[2]  J. Leonard,et al.  Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity. , 1999, Blood.

[3]  J. Bertino,et al.  Drug resistance in colon cancer. , 1999, Seminars in oncology.

[4]  F. Behm,et al.  Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. , 1999, Blood.

[5]  G. Mufti,et al.  Effect of costimulation and the microenvironment on antigen presentation by leukemic cells. , 1999, Blood.

[6]  S. Fujii,et al.  Analysis of a Chronic Myelogenous Leukemia Patient Vaccinated with Leukemic Dendritic Cells Following Autologous Peripheral Blood Stem Cell Transplantation , 1999, Japanese journal of cancer research : Gann.

[7]  J. Allison,et al.  In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Foà,et al.  CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. , 1999, Blood.

[9]  P. Nowell,et al.  Calcium signaling induces acquisition of dendritic cell characteristics in chronic myelogenous leukemia myeloid progenitor cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[10]  B. Czerniecki,et al.  Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status, or sensitivity to biologic agents. , 1999, Blood.

[11]  E. Ulvestad,et al.  Effects of gamma-irradiation on acute myelogenous leukemia blasts: in vitro studies of proliferation, constitutive cytokine secretion, and accessory cell function during T cell activation. , 1999, Journal of hematotherapy & stem cell research.

[12]  D. Olive,et al.  Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias , 1999, European journal of immunology.

[13]  B. Czerniecki,et al.  Calcium mobilization in human myeloid cells results in acquisition of individual dendritic cell-like characteristics through discrete signaling pathways. , 1999, Journal of immunology.

[14]  W. Hiddemann,et al.  Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. , 1999, Blood.

[15]  D. Hart,et al.  Dendritic cells in chronic myelomonocytic leukaemia , 1999, British journal of haematology.

[16]  M. Rots,et al.  Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. , 1999, Blood.

[17]  O. Bruserud,et al.  In vitro culture of acute myelogenous leukemia blasts: a comparison of four different culture media. , 1999, Journal of hematotherapy.

[18]  B. Johansson,et al.  A single‐center population‐based consecutive series of 1500 cytogenetically investigated adult hematological malignancies: karyotypic features in relation to morphology, age and gender , 1999, European journal of haematology.

[19]  R. Champlin,et al.  Dendritic Cells Derived In Vitro From Acute Myelogenous Leukemia Cells Stimulate Autologous, Antileukemic T-Cell Responses , 1999 .

[20]  L. Kearney,et al.  The in-vitro generation of dendritic cells from blast cells in acute leukaemia. , 1998, British journal of haematology.

[21]  M. Martelli,et al.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. , 1998, The New England journal of medicine.

[22]  M. Rots,et al.  Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[24]  J. Harousseau.  Acute myeloid leukemia in the elderly. , 1998, Blood reviews.

[25]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[26]  J. Bertino,et al.  Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  J. Bertino,et al.  gamma-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias. , 1997, Oncology research.

[28]  B. Czerniecki,et al.  Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. , 1997, Journal of immunology.

[29]  J. Bertino.  Biomodulation of 5-fluorouracil with antifolates. , 1997, Seminars in oncology.

[30]  Antonio Lanzavecchia,et al.  Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells , 1997, Nature.

[31]  J. Bertino,et al.  Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells , 1997 .

[32]  Y. Yazaki,et al.  Protective and therapeutic immunity against leukemia induced by irradiated B7-1 (CD80)-transduced leukemic cells. , 1997, Human gene therapy.

[33]  M. Waltham,et al.  gamma-Glutamyl hydrolase from human sarcoma HT-1080 cells: characterization and inhibition by glutamine antagonists. , 1997, Molecular pharmacology.

[34]  E. Jantunen,et al.  Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients , 1997, Bone Marrow Transplantation.

[35]  J. Bertino,et al.  Functional roles of E2F in cell cycle regulation , 1997, Oncogene.

[36]  F. Sirotnak,et al.  Additional Organizational Features of the Murine Folylpolyglutamate Synthetase Gene , 1997, The Journal of Biological Chemistry.

[37]  K. Kliche,et al.  Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. , 1997, Blood.

[38]  S. Queener,et al.  Synthesis and biological evaluation of nonclassical 2,4-diamino-5-methylpyrido[2,3-d]pyrimidines with novel side chain substituents as potential inhibitors of dihydrofolate reductases. , 1997, Journal of medicinal chemistry.

[39]  M. Mazumdar,et al.  Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. , 1997, Blood.

[40]  C. Bloomfield,et al.  Clinical significance of cytogenetics in acute myeloid leukemia. , 1997, Seminars in oncology.

[41]  M. Hitt,et al.  Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. , 1996, Human gene therapy.

[42]  E. Ercikan-Abali,et al.  Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line. , 1996, Journal of the National Cancer Institute.

[43]  Lau Ce.  Transparent and gauze dressings and their effect on infection rates of central venous catheters: a review of past and current literature. , 1996 .

[44]  A. Lanzavecchia,et al.  Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation , 1996, The Journal of experimental medicine.

[45]  M. Pearson.  Guideline for Prevention of Intravascular-Device–Related Infections , 1996, Infection Control & Hospital Epidemiology.

[46]  J. Lucke,et al.  Comparison of central venous catheter dressings in bone marrow transplant recipients. , 1996, Oncology nursing forum.

[47]  J. Korenberg,et al.  Purification and Properties of Human Cytosolic Folylpoly-γ-glutamate Synthetase and Organization, Localization, and Differential Splicing of Its Gene* , 1996, The Journal of Biological Chemistry.

[48]  D. Longo,et al.  Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. , 1996, Journal of immunology.

[49]  R. Arceci,et al.  Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. , 1996, Blood.

[50]  A. Fornace,et al.  The two faces of tumor suppressor p53. , 1996, The American journal of pathology.

[51]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[52]  G. Demers,et al.  Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. , 1996, Cancer research.

[53]  G. Wahl,et al.  Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[54]  J. Allison,et al.  Manipulation of costimulatory signals to enhance antitumor T-cell responses. , 1995, Current opinion in immunology.

[55]  J. Schornagel,et al.  Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein. , 1995, Cancer research.

[56]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[57]  S. Mackinnon,et al.  Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. , 1995, Blood.

[58]  E. Gilboa,et al.  Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes , 1995, The Journal of experimental medicine.

[59]  G. Wahl,et al.  Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[60]  C. Janse,et al.  Stable transfection of malaria parasite blood stages. , 1995, Science.

[61]  J. Bertino,et al.  Selective treatment of SCID mice bearing methotrexate-transport-resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin protection. , 1995, Blood.

[62]  M. Kastan,et al.  Growth factor modulation of p53-mediated growth arrest versus apoptosis. , 1995, Genes & development.

[63]  D. Livingston,et al.  Multiple members of the E2F transcription factor family are the products of oncogenes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[64]  P. Gimotty,et al.  Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. , 1995, Blood.

[65]  L. Mermel,et al.  A prospective, randomized trial of gauze and two polyurethane dressings for site care of pulmonary artery catheters: Implications for catheter management , 1994, Critical care medicine.

[66]  M. Relling,et al.  Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia , 1994 .

[67]  L. Guthertz,et al.  Aeromonas species in septicemia: laboratory characteristics and clinical observations. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[68]  E. Estey,et al.  Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia , 1994 .

[69]  W. Hong,et al.  Overexpression of E2F‐1 in rat embryo fibroblasts leads to neoplastic transformation. , 1994, The EMBO journal.

[70]  M. Fleisher.  Antifolate Analogs: Mechanism of Action, Analytical Methodology, and Clinical Efficacy , 1993, Therapeutic drug monitoring.

[71]  P. Dietrich,et al.  Cutaneous infection due to Aspergillus species after transthoracic lung biopsy. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[72]  W. Webb,et al.  Percutaneous transthoracic needle biopsy in AIDS: analysis in 32 patients. , 1993, Radiology.

[73]  Y. G. Assaraf.  Characterization by flow cytometry and fluorescein-methotrexate labeling of hydrophilic and lipophilic antifolate resistance in cultured mammalian cells. , 1993, Anti-cancer drugs.

[74]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[75]  Ying Wang,et al.  Acquisition of Resistance to Antifolates Caused by Enhanced γ-Glutamyl Hydrolase Activity , 1993 .

[76]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[77]  C. Bloomfield.  Prognostic factors for selecting curative therapy for adult acute myeloid leukemia. , 1992, Leukemia.

[78]  F. Sirotnak,et al.  Facilitated transport of methotrexate polyglutamates into lysosomes derived from S180 cells. Further characterization and evidence for a simple mobile carrier system with broad specificity for homo- or heteropeptides bearing a C-terminal glutamyl moiety. , 1992, The Journal of biological chemistry.

[79]  J. DeSpain.  Dermatologic toxicity of chemotherapy. , 1992, Seminars in oncology.

[80]  A. Look,et al.  Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1992, Blood.

[81]  P. Steinherz,et al.  Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia , 1992 .

[82]  F. Sirotnak,et al.  Metabolic turnover of methotrexate polyglutamates in lysosomes derived from S180 cells. Definition of a two-step process limited by mediated lysosomal permeation of polyglutamates and activating reduced sulfhydryl compounds. , 1992, The Journal of biological chemistry.

[83]  G P Samsa,et al.  Transparent polyurethane film as an intravenous catheter dressing. A meta-analysis of the infection risks. , 1992, JAMA.

[84]  B. Farooqi,et al.  Myonecrosis due to Aeromonas hydrophila following insertion of an intravenous cannula: case report and review. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[85]  M. Bar‐eli,et al.  Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia , 1991 .

[86]  E. Larson,et al.  A comparison of transparent adherent and dry sterile gauze dressings for long-term central catheters in patients undergoing bone marrow transplant. , 1991, Oncology nursing forum.

[87]  I. Judson,et al.  ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. , 1991, Cancer research.

[88]  W J Martone,et al.  Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. , 1991, The American journal of medicine.

[89]  R. Gaynes,et al.  Major trends in the microbial etiology of nosocomial infection. , 1991, The American journal of medicine.

[90]  G. Bodey,et al.  Spectrum of Aeromonas and Plesiomonas infections in patients with cancer and AIDS. , 1991, Experientia.

[91]  J. Shuster,et al.  Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. , 1990, Blood.

[92]  A. Cowman,et al.  Chemotherapy and drug resistance in malaria. , 1990, International journal for parasitology.

[93]  S. Nimer,et al.  Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  S. Crawford,et al.  Biopsy diagnosis and clinical outcome of persistent focal pulmonary lesions after marrow transplantation. , 1989, Transplantation.

[95]  J. J. van den Oord,et al.  Plasmacytoid monocytes (so‐called plasmacytoid T cells) in Hodgkin's disease , 1989, The Journal of pathology.

[96]  J. Conly,et al.  A prospective, randomized study comparing transparent and dry gauze dressings for central venous catheters. , 1989, The Journal of infectious diseases.

[97]  C. Svensson,et al.  'Tegaderm' dressings prevent recolonization of chlorhexidine-treated skin. , 1987, The Journal of hospital infection.

[98]  C. Sherlock,et al.  Does Aeromonas hydrophila preferentially colonize the bowels of patients with hematologic malignancies? , 1987, Diagnostic microbiology and infectious disease.

[99]  S. Rodenhuis,et al.  Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells. , 1986, Cancer research.

[100]  R. Martin,et al.  Protection of indwelling vascular catheters: Incidence of bacterial contamination and catheter‐related sepsis , 1985, Critical care medicine.

[101]  L. Elting,et al.  Bacteremia caused by Aeromonas species in hospitalized cancer patients. , 1985, Reviews of infectious diseases.

[102]  E. Larson,et al.  Hickman Catheter Infections in Patients With Malignancies , 1984, Medicine.

[103]  S. Albelda,et al.  Role of fiberoptic bronchoscopy in the diagnosis of invasive pulmonary aspergillosis in patients with acute leukemia. , 1984, The American journal of medicine.

[104]  P. Heckerling,et al.  Aeromonas hydrophila myonecrosis and gas gangrene in a nonimmunocompromised host. , 1983, Archives of internal medicine.

[105]  J. Abrahm,et al.  A prospective study of prolonged central venous access in leukemia. , 1982, JAMA.

[106]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[107]  N. Patt,et al.  Fatal pulmonary hemorrhage after percutaneous aspiration lung biopsy. , 1974, The American review of respiratory disease.

[108]  T. Lister,et al.  Immunotherapy for Acute Myelogenous Leukaemia , 1973, British Journal of Cancer.

[109]  J. Bertino,et al.  Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. , 1969, The Journal of clinical investigation.

[110]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[111]  E. Ercikan-Abali,et al.  Use of variants of dihydrofolate reductase in gene transfer to produce resistance to methotrexate and trimetrexate. , 1999, Progress in experimental tumor research.

[112]  A. Bernard,et al.  Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  J. Bertino,et al.  Increased methotrexate polyglutamylation in acute megakaryocytic leukemia (M7) compared to other subtypes of acute myelocytic leukemia , 1997, Leukemia.

[114]  Dendritic Cells: Unique Leukocyte Populations Which Control the Primary , 1997 .

[115]  M. Pearson.  Guideline for prevention of intravascular device-related infections. Part I. Intravascular device-related infections : an overview. The Hospital Infection Control Practices Advisory Committee , 1996 .

[116]  M. Waltham,et al.  Acute monocytic leukemia: a myeloid leukemia subset that may be sensitive to methotrexate. , 1995, Leukemia.

[117]  J. Rowley,et al.  Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. , 1995, Leukemia.

[118]  J. Bertino,et al.  A phase II study of continuous infusion of trimetrexate in patients with refractory acute leukemia. , 1995, Cancer investigation.

[119]  F. M. Huennekens,et al.  The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. , 1994, Advances in enzyme regulation.

[120]  J. Bertino,et al.  Karnofsky memorial lecture. Ode to methotrexate. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  M. Waltham,et al.  Increased activity of gamma-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate (MTX). , 1993, Advances in experimental medicine and biology.

[122]  W. Gold,et al.  Aeromonas hydrophila infections of skin and soft tissue: report of 11 cases and review. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[123]  James T. Lin,et al.  Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. , 1993, Leukemia.

[124]  J. Schornagel,et al.  Measurement of folylpolyglutamate synthetase activity in head and neck squamous carcinoma cell lines and clinical samples using a new rapid separation procedure. , 1992, Oncology research.

[125]  H. Dupont,et al.  Aeromonas species: role as human pathogens. , 1992, Current clinical topics in infectious diseases.

[126]  J. Bertino,et al.  Update on trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties. , 1991, Cancer investigation.

[127]  B. Schweitzer,et al.  Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia. , 1991, Leukemia research.

[128]  R. Tarver,et al.  Transthoracic aspiration needle biopsy: value in the diagnosis of pulmonary infections. , 1989, AJR. American journal of roentgenology.

[129]  M. Dryden,et al.  Aeromonas Septicemia: Relationship of Species and Clinical Features , 1989, Pathology.

[130]  M. Lederman,et al.  Nonsurgical cure of pulmonary mucormycosis. , 1984, The American journal of the medical sciences.

[131]  J. Rayner,et al.  Aeromonas hydrophila septicaemia producing ecthyma gangrenosum in a child with leukaemia. , 1977, Scandinavian journal of infectious diseases.